Literature DB >> 7536649

Localization of the complement membrane attack complex inhibitor (CD59) in human conjunctiva and lacrimal gland.

D S Bardenstein1, Y Dietz, J H Lass, M E Medof.   

Abstract

Recent studies have established that complement is present in the eye and participates in ocular defense. The mechanisms by which ocular tissues are protected from bystander injury arising from local activation of the cascade, however, have not been characterized. Decay accelerating factor (DAF or CD55) and the membrane inhibitor of reactive lysis (MIRL or CD59) are cell surface regulatory proteins that protect blood cells from uptake of autologous C3b and polymerization of autologous C9 on their surfaces. In previous studies, we found that DAF is expressed in high levels on corneal, conjunctival, and lacrimal gland acinar surfaces. In this study we assayed ocular and lacrimal gland tissues for CD59. Immunohistochemical analyses demonstrated large amounts of the protein the same locations. The presence of CD59 in these sites is consistent with the proposal that CD59 functions together with DAF in protecting ocular tissues from autologous complement-mediated injury.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7536649     DOI: 10.3109/02713689409015085

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  11 in total

1.  Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59.

Authors:  J H Sohn; H J Kaplan; H J Suk; P S Bora; N S Bora
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-12       Impact factor: 4.799

2.  Tears contain the complement regulator CD59 as well as decay-accelerating factor (DAF).

Authors:  E Cocuzzi; L B Szczotka; W G Brodbeck; D S Bardenstein; T Wei; M E Medof
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

3.  Ocular Glands Become Infected Secondarily to Infectious Keratitis and Play a Role in Corneal Resistance to Infection.

Authors:  Micaela L Montgomery; Michelle C Callegan; Kevin K Fuller; Daniel J J Carr
Journal:  J Virol       Date:  2019-07-30       Impact factor: 5.103

4.  Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins.

Authors:  J H Sohn; H J Kaplan; H J Suk; P S Bora; N S Bora
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-10       Impact factor: 4.799

5.  Blockage of complement regulators in the conjunctiva and within the eye leads to massive inflammation and iritis.

Authors:  D S Bardenstein; C J Cheyer; C Lee; E Cocuzzi; M Mizuno; N Okada; M E Medof
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

Review 6.  The role of complement system in ocular diseases including uveitis and macular degeneration.

Authors:  Purushottam Jha; Puran S Bora; Nalini S Bora
Journal:  Mol Immunol       Date:  2007-09       Impact factor: 4.407

7.  Decay accelerating factor is essential for successful corneal engraftment.

Authors:  A Esposito; B Suedekum; J Liu; F An; J Lass; M G Strainic; F Lin; P Heeger; M E Medof
Journal:  Am J Transplant       Date:  2010-01-05       Impact factor: 8.086

8.  Induction of interleukin-6 in human retinal epithelial cells by an attenuated Herpes simplex virus vector requires viral replication and NFkappaB activation.

Authors:  Suping Cai; Curtis R Brandt
Journal:  Exp Eye Res       Date:  2007-12-03       Impact factor: 3.467

9.  Both freshly prepared and frozen-stored amniotic membrane cells express the complement inhibitor CD59.

Authors:  Agnes Füst; Eva Pállinger; Adrienn Stündl; Eszter Kovács; László Imre; Sára Tóth; János Németh
Journal:  ScientificWorldJournal       Date:  2012-05-22

Review 10.  Dry eye as a mucosal autoimmune disease.

Authors:  Michael E Stern; Chris S Schaumburg; Stephen C Pflugfelder
Journal:  Int Rev Immunol       Date:  2013-02       Impact factor: 5.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.